vs
Side-by-side financial comparison of Pediatrix Medical Group, Inc. (MD) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
Medpace Holdings, Inc. is the larger business by last-quarter revenue ($708.5M vs $493.8M, roughly 1.4× Pediatrix Medical Group, Inc.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs 6.8%, a 12.3% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs -1.7%). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs -0.1%).
Pediatrix Medical Group, Inc. is a leading U.S. specialized medical service provider focusing on maternal-fetal care, neonatology, pediatric cardiology and other pediatric subspecialties. It partners with U.S. healthcare facilities to deliver evidence-based care to women, newborns and children.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
MD vs MEDP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $493.8M | $708.5M |
| Net Profit | $33.7M | $135.1M |
| Gross Margin | — | — |
| Operating Margin | 9.9% | 21.6% |
| Net Margin | 6.8% | 19.1% |
| Revenue YoY | -1.7% | 32.0% |
| Net Profit YoY | 10.5% | 15.5% |
| EPS (diluted) | $0.40 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $493.8M | $708.5M | ||
| Q3 25 | $492.9M | $659.9M | ||
| Q2 25 | $468.8M | $603.3M | ||
| Q1 25 | $458.4M | $558.6M | ||
| Q4 24 | $502.4M | $536.6M | ||
| Q3 24 | $511.2M | $533.3M | ||
| Q2 24 | $504.3M | $528.1M | ||
| Q1 24 | $495.1M | $511.0M |
| Q4 25 | $33.7M | $135.1M | ||
| Q3 25 | $71.7M | $111.1M | ||
| Q2 25 | $39.3M | $90.3M | ||
| Q1 25 | $20.7M | $114.6M | ||
| Q4 24 | $30.5M | $117.0M | ||
| Q3 24 | $19.4M | $96.4M | ||
| Q2 24 | $-153.0M | $88.4M | ||
| Q1 24 | $4.0M | $102.6M |
| Q4 25 | 9.9% | 21.6% | ||
| Q3 25 | 13.8% | 21.5% | ||
| Q2 25 | 12.8% | 20.9% | ||
| Q1 25 | 7.0% | 20.3% | ||
| Q4 24 | 7.8% | 23.4% | ||
| Q3 24 | 6.6% | 21.1% | ||
| Q2 24 | -31.3% | 19.9% | ||
| Q1 24 | 3.2% | 20.4% |
| Q4 25 | 6.8% | 19.1% | ||
| Q3 25 | 14.5% | 16.8% | ||
| Q2 25 | 8.4% | 15.0% | ||
| Q1 25 | 4.5% | 20.5% | ||
| Q4 24 | 6.1% | 21.8% | ||
| Q3 24 | 3.8% | 18.1% | ||
| Q2 24 | -30.3% | 16.7% | ||
| Q1 24 | 0.8% | 20.1% |
| Q4 25 | $0.40 | $4.65 | ||
| Q3 25 | $0.84 | $3.86 | ||
| Q2 25 | $0.46 | $3.10 | ||
| Q1 25 | $0.24 | $3.67 | ||
| Q4 24 | $0.37 | $3.67 | ||
| Q3 24 | $0.23 | $3.01 | ||
| Q2 24 | $-1.84 | $2.75 | ||
| Q1 24 | $0.05 | $3.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $375.2M | $497.0M |
| Total DebtLower is stronger | $570.5M | — |
| Stockholders' EquityBook value | $865.9M | $459.1M |
| Total Assets | $2.2B | $2.0B |
| Debt / EquityLower = less leverage | 0.66× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $375.2M | $497.0M | ||
| Q3 25 | $340.1M | $285.4M | ||
| Q2 25 | $224.7M | $46.3M | ||
| Q1 25 | $99.0M | $441.4M | ||
| Q4 24 | $229.9M | $669.4M | ||
| Q3 24 | $103.8M | $656.9M | ||
| Q2 24 | $19.4M | $510.9M | ||
| Q1 24 | $8.0M | $407.0M |
| Q4 25 | $570.5M | — | ||
| Q3 25 | $577.2M | — | ||
| Q2 25 | $583.9M | — | ||
| Q1 25 | $590.5M | — | ||
| Q4 24 | $597.1M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $865.9M | $459.1M | ||
| Q3 25 | $890.7M | $293.6M | ||
| Q2 25 | $833.8M | $172.4M | ||
| Q1 25 | $789.2M | $593.6M | ||
| Q4 24 | $764.9M | $825.5M | ||
| Q3 24 | $732.5M | $881.4M | ||
| Q2 24 | $706.5M | $763.6M | ||
| Q1 24 | $856.2M | $671.5M |
| Q4 25 | $2.2B | $2.0B | ||
| Q3 25 | $2.2B | $1.8B | ||
| Q2 25 | $2.1B | $1.6B | ||
| Q1 25 | $2.0B | $1.9B | ||
| Q4 24 | $2.2B | $2.1B | ||
| Q3 24 | $2.1B | $2.1B | ||
| Q2 24 | $2.0B | $1.9B | ||
| Q1 24 | $2.2B | $1.8B |
| Q4 25 | 0.66× | — | ||
| Q3 25 | 0.65× | — | ||
| Q2 25 | 0.70× | — | ||
| Q1 25 | 0.75× | — | ||
| Q4 24 | 0.78× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $114.1M | $192.7M |
| Free Cash FlowOCF − Capex | — | $188.1M |
| FCF MarginFCF / Revenue | — | 26.6% |
| Capex IntensityCapex / Revenue | — | 0.6% |
| Cash ConversionOCF / Net Profit | 3.39× | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | — | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $114.1M | $192.7M | ||
| Q3 25 | $137.3M | $246.2M | ||
| Q2 25 | $137.2M | $148.5M | ||
| Q1 25 | $-117.5M | $125.8M | ||
| Q4 24 | $133.0M | $190.7M | ||
| Q3 24 | $91.8M | $149.1M | ||
| Q2 24 | $107.0M | $116.4M | ||
| Q1 24 | $-125.2M | $152.7M |
| Q4 25 | — | $188.1M | ||
| Q3 25 | — | $235.5M | ||
| Q2 25 | — | $142.4M | ||
| Q1 25 | — | $115.8M | ||
| Q4 24 | — | $183.0M | ||
| Q3 24 | — | $138.5M | ||
| Q2 24 | — | $103.5M | ||
| Q1 24 | — | $147.2M |
| Q4 25 | — | 26.6% | ||
| Q3 25 | — | 35.7% | ||
| Q2 25 | — | 23.6% | ||
| Q1 25 | — | 20.7% | ||
| Q4 24 | — | 34.1% | ||
| Q3 24 | — | 26.0% | ||
| Q2 24 | — | 19.6% | ||
| Q1 24 | — | 28.8% |
| Q4 25 | — | 0.6% | ||
| Q3 25 | — | 1.6% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 1.8% | ||
| Q4 24 | — | 1.4% | ||
| Q3 24 | — | 2.0% | ||
| Q2 24 | — | 2.4% | ||
| Q1 24 | — | 1.1% |
| Q4 25 | 3.39× | 1.43× | ||
| Q3 25 | 1.91× | 2.22× | ||
| Q2 25 | 3.49× | 1.65× | ||
| Q1 25 | -5.66× | 1.10× | ||
| Q4 24 | 4.36× | 1.63× | ||
| Q3 24 | 4.72× | 1.55× | ||
| Q2 24 | — | 1.32× | ||
| Q1 24 | -31.03× | 1.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
